JPMorgan raised the firm’s price target on Rapt Therapeutics to $35 from $32 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT:
- Rapt Therapeutics announces publication of Phase 1a/1n trial of zelnecirnon
- Rapt Therapeutics price target lowered to $42 from $48 at Wells Fargo
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results
- Rapt Therapeutics reports Q3 EPS (82c), consensus (75c)
- Rapt Therapeutics reports ‘positive’ data from Phase 2 FLX475 combo trial